For decades, scientists have known that the pancreas plays a central role in diabetes, but the precise reasons some people develop the disease while others remain healthy have remained elusive. A new NIH-funded study, published this month in Nature Communications, takes a major step toward solving that puzzle by mapping the cellular landscape of the human pancreas in unprecedented detail.
The findings suggest that subtle differences in the makeup of pancreatic islets, the tiny clusters of hormone-producing cells that regulate blood sugar, may help explain why diabetes risk varies so dramatically between individuals, sexes, and ancestral backgrounds.
What the New Pancreas Atlas Found
Researchers from the Integrated Islet Distribution Program (IIDP) at City of Hope and Indiana University School of Medicine analyzed pancreatic islets from 299 organ donors, one of the largest such datasets ever assembled. The work was published on May 12, 2026, in Nature Communications.
On average, the team reported, islets are composed of three main cell types:
- Beta cells (58%) — produce insulin, the hormone that lowers blood sugar.
- Alpha cells (34%) — produce glucagon, which raises blood sugar when it dips too low.
- Delta cells (8%) — produce somatostatin, a regulator that fine-tunes both signals.
But those averages mask wide individual variation. Some donors had far more beta cells than others, and the proportion of insulin-producing cells correlated directly with how strongly the islets responded to glucose. In other words, the recipe matters more than the architecture: islets with a higher share of beta cells released insulin more robustly, regardless of how the cells were physically arranged.
Why Pancreatic Islet Cells Matter
Pancreatic islets, sometimes called the islets of Langerhans, occupy only about 1 to 2 percent of pancreatic tissue, yet they orchestrate the body’s entire glucose-regulation system. When beta cells fail to produce enough insulin, blood sugar climbs and type 2 diabetes can develop; when the immune system destroys beta cells outright, the result is type 1 diabetes.
According to the Centers for Disease Control and Prevention, roughly 38 million Americans live with diabetes and an additional 98 million have prediabetes. Understanding the cellular roots of those numbers has been a long-standing research goal.
Surprising Differences by Sex and Ancestry
One of the study’s most striking findings was that islet composition is not uniform across populations. Female donors tended to have a higher proportion of alpha cells and a lower proportion of beta cells than male donors. The researchers also observed measurable differences in beta cell proportions linked to ancestral background.
These observations may help explain why diabetes risk and disease progression vary across demographic groups, and they reinforce a growing recognition in medicine that biological diversity should be reflected in research. Historically, pancreas and metabolic studies have skewed toward donors of European ancestry, which can limit how broadly findings apply.
New Clues to Type 1 and Type 2 Diabetes Risk
The atlas does more than catalog cells. By layering genetic data on top of cellular profiles, the team found that individual variation in islet composition appears to interact with inherited risk factors for both type 1 and type 2 diabetes. People whose islets carry fewer or less responsive beta cells may have a smaller insulin reserve to draw on when challenged by weight gain, aging, or autoimmune attack.
This concept of beta-cell reserve has been hypothesized for years, but the new dataset provides one of the clearest population-scale views of how that reserve varies in healthy humans. The researchers note that pairing single-cell maps with genetic and clinical data could eventually help identify people at higher risk before blood sugar abnormalities appear.
What This Means for Future Diabetes Care
The atlas itself is a research tool, not a clinical test. Patients cannot yet ask a doctor to assess their personal islet composition. But the work opens several practical directions:
- Earlier risk stratification. Future biomarkers could flag people with low beta-cell reserve, allowing for earlier prevention efforts.
- Better drug targets. Drugs that protect or regenerate beta cells, including some next-generation GLP-1 therapies, may be prioritized for those most likely to benefit.
- Improved transplant matching. Islet transplantation, used to treat severe type 1 diabetes, may become more effective if donor islets are matched by composition rather than volume alone.
Carmella Evans-Molina, M.D., Ph.D., of Indiana University School of Medicine, who helped lead the work, has previously emphasized that diabetes prevention will likely require treatments tailored to the biology of individual patients. Research like this is the scaffolding for that future.
Supporting Pancreatic and Metabolic Health Today
While the new atlas points toward a more personalized future, the foundations of metabolic health remain consistent with decades of evidence. Studies indicate that several everyday habits help preserve beta-cell function and insulin sensitivity:
- Prioritize whole foods. Diets rich in vegetables, legumes, fish, whole grains, and minimally processed fats are associated with lower diabetes risk in long-term cohort studies.
- Move regularly. Research suggests that even moderate activity, including walking after meals, can meaningfully improve glucose regulation.
- Sleep enough. Chronic short sleep is linked to impaired insulin sensitivity in NIH-supported research.
- Manage weight gradually. Modest, sustained weight loss can reverse early metabolic dysfunction for many adults with prediabetes.
- Get screened. Periodic glucose or A1C testing is recommended for adults with risk factors, including family history, excess weight, or a history of gestational diabetes.
The Bigger Picture
The pancreas has long been one of the body’s least-understood organs, in part because it is fragile, deep inside the abdomen, and difficult to study in living people. Large, donor-driven projects like the IIDP are finally beginning to illuminate its inner workings at the single-cell level.
For the more than 130 million Americans living with diabetes or prediabetes, the practical impact of any single study is gradual. But each new map, dataset, and genetic insight pushes the field closer to the goal that has driven diabetes research for a century: predicting, preventing, and ultimately reversing a disease that touches almost every family.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.